PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-8.57%
Cash & equivalents declining -8.57% while AXSM's grows 3.70%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-8.57%
Below half of AXSM's 3.70%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.59%
Other current assets growth < half of AXSM's 13.58%. David Dodd sees a leaner approach to short-term items.
-8.67%
Below half of AXSM's 3.47%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-8.20%
0.5-0.75x AXSM's -15.67%. Martin Whitman might see a risk of falling behind in asset investment or shifting strategy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.26%
Less than half of AXSM's -1.13%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-7.12%
≥ 1.5x AXSM's -3.35%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-8.62%
Below half of AXSM's 2.41%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-100.00%
Less than half of AXSM's 4.75%. David Dodd sees a more disciplined AP approach or lower volume.
-100.00%
Higher Short-Term Debt Growth compared to AXSM's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1405.81%
Similar yoy changes to AXSM's 1725.77%. Walter Schloss finds parallel near-term liability trends.
-20.28%
Less than half of AXSM's 5.15%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.40%
Less than half of AXSM's 5.24%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-4.61%
Less than half of AXSM's 5.21%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-3.23%
Below half AXSM's -6.57%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.84%
1.25-1.5x AXSM's -9.68%. Bruce Berkowitz notes an above-average equity expansion.
-8.62%
Below half AXSM's 2.41%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
-100.00%
Both AXSM and the company show zero Total Investments Growth.
-7.46%
Less than half of AXSM's 0.26%. David Dodd sees less overall debt expansion vs. competitor.
8.60%
Less than half of AXSM's -9.03%. David Dodd sees better deleveraging or stronger cash buildup than competitor.